Charles River Laboratories | CRL - Pre Tax Profit


Charles River Laboratories reported $-29.94M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
Agilent USD 408M 44M Mar/2026
Align Technology USD 148.69M 193K Jun/2026
Bio-Rad Laboratories USD 542.1M 1.23B Jun/2026
Bruker USD 117M 95.1M Jun/2026
Cardinal Health USD 782M 390M Jun/2026
Charles River Laboratories USD -29.94M 264.16M Mar/2026
Cigna USD 2.27B 453M Mar/2026
CVS Health USD 3.94B 2.58B Mar/2026
Danaher USD 1.08B 157M Jun/2026
Dentsply International USD -42M 105M Mar/2026
Elevance Health USD 2.16B 146M Jun/2026
Humana USD 1.6B 2.61B Mar/2026
Illumina USD 260M 103M Jun/2026
Incyte USD 751.51M 407.91M Jun/2026
Intrexon USD -60.48M 27.09M Jun/2024
IQVIA Holdings USD 301M 5.92B Jun/2026
Laboratory Of America USD 8.61B 121.8M Jun/2026
Lakefront Biotherapeutics EUR 13.96M 769.2M Mar/2026
Lonza CHF 624M 197M Dec/2024
McKesson USD 2.12B 495M Mar/2026
Merck EUR 869M 468M Mar/2026
Mettler Toledo International USD 209.66M 119.42M Mar/2026
Novartis USD 4.27B 430M Jun/2026
Pfizer USD -653M 5.84B Jun/2026
Quest Diagnostics USD 334M 4M Mar/2026
Revvity USD 187.24M 137.25M Jun/2026
Thermo Fisher Scientific USD 1.73B 389M Mar/2026
United Therapeutics USD 372.7M 54.4M Jun/2026
UnitedHealth USD 7.36B 600M Jun/2026
Veradigm USD 35.3M 13.95M Sep/2022
Waters USD 356M 444M Jun/2026
West Pharmaceutical Services USD 180.1M 18.6M Mar/2026